{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreid3aefkjkrqzvgvkzikavxrxduhqejqftlfw5pqedzsr3wbqrdsty",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mogwxx56mla2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie6xuudpu35wvvcdjhceynk74oj5mdyfakiepnu5jyp3gil4z4jde"
    },
    "mimeType": "image/webp",
    "size": 166904
  },
  "path": "/releases/2026/06/260615033837.htm",
  "publishedAt": "2026-06-16T08:07:39.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2 diabetes: stronger protection against bone fractures while delivering greater weight loss. Researchers analyzing health records from nearly 60,000 adults found that people taking semaglutide experienced about 15% fewer fractures than those using other common weight-loss medications, despite losing more weight.",
  "title": "Semaglutide (Ozempic) linked to fewer bone fractures despite greater weight loss"
}